Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 35, 2022 - Issue 6
Submit an article Journal homepage
35
Views
0
CrossRef citations to date
0
Altmetric
Case Studies

Successful treatment of recurrent esophageal squamous cell carcinoma with muscle metastasis using capecitabine and cetuximab

Soroush Shahrokha Internal Medicine Residency Program, University of Houston College of Medicine/HCA Houston Healthcare – Kingwood, Houston, TexasORCID Iconhttps://orcid.org/0000-0003-3931-5395
, DO, MScORCID Icon,
Soraya Salmanianb Onco-Pathology Research Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
, MD,
Ahmad Foroughic Department of Radiation Oncology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
, MD &
Mohadese Shahinc Department of Radiation Oncology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, IranCorrespondence[email protected]
, MD
Pages 834-836 | Received 27 Apr 2022, Accepted 07 Jul 2022, Published online: 25 Jul 2022

  • Mosavi-Jarrahi A, Mohagheghi MA. Epidemiology of esophageal cancer in the high-risk population of Iran. Asian Pac J Cancer Prev. 2006;7(3):375–380.
  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clinic. 2022;72(1):7–33. doi:10.3322/caac.21708.
  • Wu SG, Zhang WW, Sun JY, Li FY, Lin Q, He ZY. Patterns of distant metastasis between histological types in esophageal cancer. Front Oncol. 2018;8(302). doi:10.3389/fonc.2018.00302.
  • Shaheen O, Ghibour A, Alsaid B. Esophageal cancer metastases to unexpected sites: a systematic review. Gastroenterol Res Pract. 2017;2017:1657310. doi:10.1155/2017/1657310.
  • Tachimori Y, Nagai Y, Kanamori N, Hokamura N, Igaki H. Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system. Dis Esophag. 2011;24(1):33–38. doi:10.1111/j.1442-2050.2010.01086.x.
  • El Abiad JM, Hales RK, Levin AS, Morris CD. Soft-tissue metastases from esophageal cancer. J Gastrointest Surg. 2019;23(9):1721–1728. doi:10.1007/s11605-019-04160-w.
  • Fujimoto Y, Nakashima Y, Sasaki S, et al. Chemoradiotherapy for solitary skeletal muscle metastasis from oesophageal cancer: case report and brief literature review. Anticancer Res. 2017;37(10):5687–5691. doi:10.21873/anticanres.12005.
  • Cincibuch J, Mysliveček M, Melichar B, et al. Metastases of esophageal carcinoma to skeletal muscle: single center experience. World J Gastroenterol. 2012;18(35):4962–4966. doi:10.3748/wjg.v18.i35.4962.
  • Janmaat VT, Steyerberg EW, van der Gaast A, et al. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev. 2017;11(11):CD004063. doi:10.1002/14651858.CD004063.pub4.
  • Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14(7):627–637. doi:10.1016/S1470-2045(13)70136-0.
  • Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):481–489. doi:10.1016/S1470-2045(13)70096-2.
  • Eyck BM, van Lanschot JJB, Hulshof MCCM, et al; CROSS Study Group. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39(18):1995–2004. doi:10.1200/JCO.20.03614.
  • Huang ZH, Ma XW, Zhang J, Li X, Lai NL, Zhang SX. Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials. BMC Cancer. 2018;18(1):1170. doi:10.1186/s12885-018-5040-z.
  • Dahan L, Sadok A, Formento JL, Seitz JF, Kovacic H. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol. 2009;158(2):610–620. doi:10.1111/j.1476-5381.2009.00341.x.
  • Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer—is the water getting muddy? Acta Oncol. 2010;49(3):278–286. doi:10.3109/02841860903536010.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.